等待内容更新

英文药名：Suglat Tablets（Ipragliflozin L-Proline）

中文药名：伊格列净L-脯氨酸片

生产厂家：安斯泰来

スーグラ錠25mg／スーグラ錠50mg

治疗类别名称
选择性SGLT2抑制剂
-2型糖尿病治疗药物-
商標名 
Suglat Tablets 25mg
Suglat Tablets 50mg
一般名 
イプラグリフロジン　L-プロリン（Ipragliflozin L-Proline） 
化学名 
（1S）-1,5-Anhydro-1-C -{3-［（1-benzothiophen-2-yl）methyl］-4-fluorophenyl}-D-glucitol-（2S）-pyrrolidine-2-carboxylic acid（1：1） 
構造式

 

分子式 
C21H21FO5S・C5H9NO2 
分子量 
519.58 
融点 
約205℃（分解） 
性状 
L- Furojin脯氨酸是一种结晶或白色至淡棕白色带粉。易溶于二甲亚砜，乙醇（99.5）微溶，并且几乎不溶于水。
成份；Ipragliflozin L-Proline 伊格列净 L-脯氨酸
药效药理
1. 作用机序 
Na +/葡萄糖共转运体（SGLT：钠葡萄糖共转运体）是葡萄糖的主动运输的转运进入细胞的Na +的浓度梯度作为驱动力。为SGLT1和人类SGLT2的功能，在胃肠道吸收葡萄糖SGLT1，葡萄糖再吸收是SGLT2在肾近端小管，发挥主要作用的每个已变得显而易见。Furojin抑制SGLT2在肾近端小管中表达，通过在血液中排出多余的葡萄糖身体外部施加的降血糖作用
2. 药理作用
(1) SGLT2抑制作用
Furojin显示了人SGLT2的选择性抑制作用，50％抑制浓度（IC 50值）为7.38nmol/ L。对于SGLT1 IC50值是1880nmol/L。
(2) 促进作用和降血糖作用的尿葡萄糖排泄
Furojin是正常小鼠，由单一的口服给药在烟酰胺/STZ诱导2温和型糖尿病小鼠和2型糖尿病KK-A y小鼠在给药后增加了长达24小时的累积尿葡萄糖排泄。此外，利插李Furojin抑制小鼠中的液体营养负荷后增加的血糖值由单一口服施用。此外，利插锂Furojin在2型糖尿病KK-A y小鼠和db/db小鼠，它表现出由单个28天天反复口服给药的HbA1c降低效果。
用于治疗2型糖尿病，当本剂50毫克，100毫克或安慰剂每天给药一次持续14天，从在该药物给药组的基线的累积尿葡萄糖排泄的最后一次给药后的变化最多24小时量增加。另外，从在空腹血糖水平基线的变化量也增加。
适应症
2型糖尿病
剂量和用法
成人，每天一次，每次给药50毫克口服，如效果是不够，它可能会增加至每天一次100mg1同时观察整个疗程。
包装规格
片剂
25毫克：
100片（10片×10）140片（14片×10）
50毫克：
100片（10片×10）140片（14片×10）300片（瓶装）500片（10片×50）

制造和销售
安斯泰来制药公司[联盟]MSD有限公司，日本寿药业有限公司

 

 

Description

This medicine inhibits SGLT2 which resorbs glucose in the kidney, thus reducing blood glucose through the excretion of excess glucose into urine.
It is usually used for the treatment of type 2 diabetes.

Presentation

Feature

Active Ingredients

Ipragliflozin L-Proline

Effect/Efficacy

Usage/Dosage

In general, for adults, take 2 tablets (50 mg of ipragliflozin) at a time, once a day before or after breakfast. If the effect of this medicine is insufficient, it may be increased up to 4 tablets (100 mg) once a day while carefully following the course of the disease. If you have a severe hepatic impairment, the dosage may be started with low doses. Strictly follow the instructions.
If you miss a dose, skip the missed dose and continue your regular dosing schedule. You should never take two doses at one time.
If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist.
Do not stop taking this medicine unless your doctor instructs you to do so.

Cautions

Strictly follow the instructions on dietary/exercise therapy.
This medicine may cause hypoglycemic symptoms. Be aware of operating in potentially hazardous activities such as driving a car and working at heights.
Take foods containing sugar or drink juice if any hypoglycemic symptoms occur. If you are taking in conjunction with α-glucosidase inhibitors (medicines which delay the uptake of glucose) and hypoglycemic symptoms develop, you must take in glucose.
Take a larger amount of water, since this medicine may cause dehydration. Intake of water or tea is desirable, since drink including sugar such as isotonic drink may increase blood glucose.
Do not stop taking water or decrease the amount of water on your own judgment.
Stop taking the medicine if you have repeated diarrhea/vomiting or cannot take food or water continuously due to decreased appetite.

Possible adverse reactions to this medicine
The most commonly reported adverse reactions include urinary frequency, thirst, constipation, and weight loss. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
light headedness, lassitude, sweating, hunger, shaking of hands and feet [hypoglycemia]
chills, fever, flank pain, back pain, lower back pain [pyelonephritis]
Thirst/dry mouth, large urinary volume, dizziness/lightheadedness [dehydration]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Contraindication